ACORDA THERAPEUTICS
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FD... A) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
ACORDA THERAPEUTICS
Industry:
Biotechnology Developer Platform Health Care
Founded:
1995-01-01
Address:
Hawthorne, New York, United States
Country:
United States
Website Url:
http://www.acorda.com
Total Employee:
251+
Status:
Active
Contact:
(914) 347-4300
Email Addresses:
[email protected]
Total Funding:
151.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager Content Delivery Network Font Awesome Apache Mobile Non Scaleable Content IPv6 ReCAPTCHA
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2016-01-19 | Biotie Therapies | Biotie Therapies acquired by Acorda Therapeutics | 363 M USD |
2014-09-24 | Civitas Therapeutics | Civitas Therapeutics acquired by Acorda Therapeutics | 525 M USD |
2012-02-17 | Neuronex | Neuronex acquired by Acorda Therapeutics | N/A |
Investors List
Paul Capital
Paul Capital investment in Post-IPO Equity - Acorda Therapeutics
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Acorda Therapeutics
New York State Department of Health
New York State Department of Health investment in Grant - Acorda Therapeutics
Cross Atlantic Partners
Cross Atlantic Partners investment in Series B - Acorda Therapeutics
J.P. Morgan Securities Inc.
J.P. Morgan Securities Inc. investment in Series B - Acorda Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Acorda Therapeutics
MPM Capital
MPM Capital investment in Series B - Acorda Therapeutics
Forward Ventures
Forward Ventures investment in Series B - Acorda Therapeutics
ABN AMRO Fund
ABN AMRO Fund investment in Series B - Acorda Therapeutics
Easton Capital
Easton Capital investment in Series B - Acorda Therapeutics
Official Site Inspections
http://www.acorda.com Semrush global rank: 4.72 M Semrush visits lastest month: 2.01 K
- Host name: 44.233.12.198.host.secureserver.net
- IP address: 198.12.233.44
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260